BofA Finance LLC has recently filed a pricing supplement for $600,000 in contingent income notes linked to the common shares of Abbott Laboratories. This filing is significant as it illustrates BofA Finance's strategy to diversify its financial products and enhance its offerings in the competitive national commercial banking sector.

The contingent income notes, which come with a memory feature, are designed to provide investors with potential returns linked to the performance of Abbott Laboratories' shares. The notes are set to be issued on October 30, 2026, and will have an approximate three-year term unless called prior to maturity.

Background

BofA Finance LLC operates within the national commercial banks sector (SIC 6021). The company is a subsidiary of Bank of America Corporation, which guarantees the notes being issued. BofA Finance is incorporated in Delaware and has its headquarters in Charlotte, North Carolina. The company has recently filed multiple forms, including several pricing supplements, indicating an active approach to capital markets.

What the Filing Says

The filing states, "The Notes will not be listed on any securities exchange," and they are subject to the credit risk of BofA Finance LLC and Bank of America Corporation. The notes are priced at $1,000 each, with a public offering price of $600,000 for the total issuance.

Impact

This filing may affect various stakeholders, including potential investors interested in income-generating securities. The notes are designed for investors who are looking for contingent income linked to the performance of Abbott Laboratories. Additionally, the move may influence competitors in the national commercial banking sector as they observe BofA Finance's strategy in offering similar financial products.

What's Next

The next steps following this filing are not detailed in the SEC submission. However, the notes are expected to be issued on October 30, 2026, following the pricing date of October 27, 2026.